静脉免疫球蛋白市场规模、份额和成长分析（按产品、分销管道、应用和地区）- 2025-2032 年产业预测

静脉免疫球蛋白市场规模在 2023 年价值 129 亿美元，预计将从 2024 年的 138.4 亿美元增长到 2032 年的 243.2 亿美元，预测期内（2025-2032 年）的复合年增长率为 7.3%。

由于几个关键因素，静脉注射免疫球蛋白 (IVIG) 市场正在经历强劲成长。突出的因素包括老年人口的不断增长、免疫不全症盛行率的不断上升以及 IVIG 治疗方案的广泛接受。此外，患有出血性疾病和慢性脱髓鞘多发性神经炎(CIDP) 的患者数量不断增加，导致 IVIG 的仿单标示外使用增加。医疗保健领域的大量投资正在进一步推动市场扩张。此外，自体免疫疾病和其他病理状况的发病率不断上升也推动了对 IVIG 产品的需求，凸显了它们在满足多样化医疗保健需求方面的重要作用。随着这些动态的不断发展，IVIG 市场可能在未来几年内持续成长。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 次要和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024 年）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析

静脉注射免疫球蛋白市场规模（按产品和复合年增长率） (2025-2032)

• 市场概况
• IGG
• IGA
• IGM
• IGE
• IGD

静脉注射免疫球蛋白市场规模（按分销管道和复合年增长率） (2025-2032)

• 市场概况
• 医院药房
• 专业药房
• 其他的

静脉注射免疫球蛋白市场规模（依应用划分）及复合年增长率（2025-2032）

• 市场概况
• 免疫不全症
• CIDP
• 低丙种球蛋白血症
• 先天性爱滋病
• 慢性淋巴性白血病
• 重症肌无力
• 多灶性运动神经病变
• 免疫球蛋白
• 川崎病
• 格林-巴利综合症
• 其他的

静脉注射免疫球蛋白市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲国家
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前 5 家公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采用的策略
• 近期市场趋势
• 公司市场占有率分析（2024 年）
• 主要企业简介
  • 公司详细信息
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• CSL Behring（Australia）
• Grifols, SA（Spain）
• Octapharma AG（Switzerland）
• Kedrion SpA（Italy）
• Bio Products Laboratory Ltd.（United Kingdom）
• Biotest AG（Germany）
• China Biologic Products Holdings, Inc.（China）
• LFB SA（France）
• Shanghai RAAS Blood Products Co., Ltd.（China）
• ADMA Biologics, Inc.（United States）
• Sanquin Blood Supply Foundation（Netherlands）
• Kamada Ltd.（Israel）
• Emergent BioSolutions Inc.（United States）
• Hualan Biological Engineering Inc.（China）
• Green Cross Corporation（South Korea）
• Bharat Serums and Vaccines Limited（India）
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.（China）
• Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.（China）
• Guangdong Shuanglin Bio-Pharmacy Co., Ltd.（China）
• Nanjing Xinbai Pharmaceutical Co., Ltd.（China）

结论和建议

Intravenous Immunoglobulin Market size was valued at USD 12.9 billion in 2023 and is poised to grow from USD 13.84 billion in 2024 to USD 24.32 billion by 2032, growing at a CAGR of 7.3% during the forecast period (2025-2032).

The intravenous immunoglobulin (IVIG) market is witnessing robust growth driven by several pivotal factors. The rising geriatric population, increasing prevalence of immunodeficiency disorders, and broader acceptance of IVIG treatment options are notable contributors. Additionally, the off-label use of IVIG is expanding, spurred by a growing demographic of patients suffering from bleeding disorders and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Significant investments in the healthcare sector further bolster market expansion. The escalating rates of autoimmune diseases and other pathological conditions also amplify the demand for IVIG products, highlighting their essential role in meeting diverse healthcare needs. As these dynamics evolve, the IVIG market is positioned for sustained growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Intravenous Immunoglobulin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Intravenous Immunoglobulin Market Segments Analysis

Global Intravenous Immunoglobulin Market is segmented by Product, Distribution Channel, Application and region. Based on Product, the market is segmented into IGG, IGA, IGM, IGE and IGD. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Specialty Pharmacies and Other. Based on Application, the market is segmented into Immunodeficiency diseases, CIDP, Hypogammaglobulinemia, Congenital AIDS, Chronic Lymphocytic Leukemia, Myasthenia Gravis, Multifocal motor neuropathy, ITP, Kawasaki disease, Guillain-Barre syndrome and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Intravenous Immunoglobulin Market

The increasing adoption of intravenous immunoglobulin (IVIG) therapy as the primary treatment option for various rare immunological and neurological disorders, particularly primary immunodeficiency (PI) and related conditions, serves as a key driver for the growth of the intravenous immunoglobulin market. This widespread acknowledgment of IVIG as a first-line therapeutic approach underscores its effectiveness and vital role in the successful management of these diseases. As more healthcare providers and patients recognize the benefits of IVIG, the demand for this therapy continues to rise, further solidifying its importance in treating complex immunological conditions.

Restraints in the Intravenous Immunoglobulin Market

The financial implications associated with the diagnosis and treatment of demyelinating diseases create a substantial obstacle for the intravenous immunoglobulin (IVIG) market. One of the most pressing challenges is the escalating costs associated with IVIG therapy, which significantly hinder market growth. IVIG treatment generally requires administration every three to four weeks, resulting in roughly 12 to 16 treatment sessions per year. Given the average expenditure for IVIG is approximately USD 73.89 per gram, this leads to an estimated total annual cost of around USD 10,000. Such high prices can deter patients from accessing necessary treatments, putting further strain on market expansion.

Market Trends of the Intravenous Immunoglobulin Market

The Intravenous Immunoglobulin (IVIG) market is witnessing dynamic growth fueled by several significant trends transforming its landscape. A notable increase in IVIG utilization for neurological disorders underscores its expanding therapeutic applications beyond conventional uses, reflecting a broader acceptance in clinical settings. Furthermore, the incorporation of personalized medicine approaches into IVIG therapies is reshaping treatment protocols, aligning therapies with specific patient needs for improved outcomes. Additionally, the rise of novel immunomodulatory treatments contributes to this evolving market by introducing innovative therapeutic options, enhancing the treatment landscape, and paving the way for future advancements in patient care and immunoglobulin therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Intravenous Immunoglobulin Market Size by Product & CAGR (2025-2032)

• Market Overview
• IGG
• IGA
• IGM
• IGE
• IGD

Global Intravenous Immunoglobulin Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Other

Global Intravenous Immunoglobulin Market Size by Application & CAGR (2025-2032)

• Market Overview
• Immunodeficiency diseases
• CIDP
• Hypogammaglobulinemia
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal motor neuropathy
• ITP
• Kawasaki disease
• Guillain-Barre syndrome
• Others

Global Intravenous Immunoglobulin Market Size & CAGR (2025-2032)

• North America (Product, Distribution Channel, Application)
  • US
  • Canada
• Europe (Product, Distribution Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Distribution Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Distribution Channel, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Distribution Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotest AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• China Biologic Products Holdings, Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai RAAS Blood Products Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ADMA Biologics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanquin Blood Supply Foundation (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kamada Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emergent BioSolutions Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hualan Biological Engineering Inc. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Green Cross Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bharat Serums and Vaccines Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guangdong Shuanglin Bio-Pharmacy Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nanjing Xinbai Pharmaceutical Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations